Pharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis

Area of Science:

• Pulmonology
• Immunology
• Radiology

Background:

• Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by surfactant accumulation in alveoli.
• Autoimmune PAP (aPAP) is the most common form, linked to antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF).
• Diagnosis typically involves characteristic "crazy paving" patterns on CT scans and confirmation of anti-GM-CSF antibodies.

Purpose of the Study:

• To review the diagnostic criteria for autoimmune pulmonary alveolar proteinosis.
• To outline the current and emerging treatment strategies for autoimmune pulmonary alveolar proteinosis.
• To discuss the evolving understanding of aPAP pathogenesis and its therapeutic implications.

Main Methods:

• Review of diagnostic methods including chest CT, bronchoalveolar lavage (BAL) with Periodic Acid Schiff (PAS) staining, and serum antibody testing.
• Analysis of treatment guidelines and clinical trial data for autoimmune pulmonary alveolar proteinosis.
• Exploration of novel therapeutic targets based on recent pathogenetic insights.

Main Results:

• Chest CT "crazy paving" suggests PAP; PAS-positive material in BAL confirms surfactant accumulation.
• Detection of anti-GM-CSF antibodies in serum confirms the autoimmune etiology.
• Inhaled GM-CSF (molgramostim or sargramostim) is now a first-line treatment, supported by randomized controlled trials.

Conclusions:

• Autoimmune pulmonary alveolar proteinosis management has shifted towards less invasive therapies.
• Whole lung lavage remains crucial for severe respiratory failure, while inhaled GM-CSF offers a new first-line option.
• Emerging therapies targeting aPAP pathogenesis show promise for future treatment strategies.